Clinical

Dataset Information

0

Feasibility and acceptability of pre-operative exercise to improve patient outcomes after major pelvic cancer surgery: A pilot randomised controlled trial.


ABSTRACT: Interventions: Pre-operative exercise programme: The exercise programme will consist of 60 minutes individualised (one-to-one) training session with a registered physiotherapist, once a week, for 2 to 6 weeks (maximal of 6 sessions) before the patient undergoes their scheduled surgery. The last day of exercise will be the day before the patient undergoes surgery. The duration (2-6 weeks), specific exercises performed and intensity of the exercise programme will all be tailored to each patient through a health assessment, taking into consideration their current health status, physical activity level, co-morbidities and medical history. Each session will consist of 10 minutes of warm-up (walking and cycling), 40 minutes of aerobic and endurance exercises (such as cycling, treadmill and rower activity), respiratory and muscle strength exercises (breathing and weights training), and 10 minutes cool down (stretches and flexibility exercises). The aerobic and endurance exercises will be performed at 40% to 60% of the maximum heart rate and the strength training will be performed at an intensity of 40% to 60% of the one repetition maximum. Participant will be given instruction and recommendations on how to complete and progress these exercises (or similar exercises) at home (4 sessions x 60 minutes at home per week, up to the scheduled date of surgery). Furthermore, apart from the prescribed exercises, participants will be recommended to engage in moderate-intensity exercise for at least 150 minutes per week (such as walking or cycling). Home exercises will be captured in a daily exercise diary that participants will complete until the end of the exercise programme. Primary outcome(s): The feasibility of incorporating a standardised, intensive exercise programme into the pre-operative period for patients undergoing pelvic exenteration at Royal Prince Alfred Hospital. This will be determined by the number of eligible patients recruited, retention and adherence rates to the exercise programme. The retention rate will be defined as the percentage of individuals who completed the intervention. Adherence will be defined as the percentage of exercise sessions attended by those who were randomised to the intervention group. Adherence to the exercise programme will be recorded using attendance records (recorded by the study physiotherapist) / participant exercise diaries (recorded by the participant).[Feasibility will be assessed during the week before surgery (1 week pre-operative), ];The acceptability of incorporating a standardised, intensive exercise programme into the pre-operative period for patients undergoing pelvic exenteration at Royal Prince Alfred Hospital. This will be assessed by a semi structured questionnaire pre-discharge.[Acceptability will be assessed shortly before discharge after surgery (pre-hospital discharge).];The acceptability to patients of being randomised to the exercise program or usual care (satisfaction with study intervention). This will be determined by the number or eligible patients recruited to the trial (who accept being randomised to either treatment group), and by a semi structured questionnaire pre-discharge.[Acceptability of randomisation and patient satisfaction with the study intervention will be assessed at enrollment to the study and at pre-hospital discharge.] Study Design: Purpose: Treatment; Allocation: Randomised controlled trial; Masking: Blinded (masking used);Assignment: Parallel;Type of endpoint: Efficacy

DISEASE(S): Cancer-ovarian And Primary Peritoneal,Cancer-bowel-back Passage (rectum) Or Large Bowel (colon),Cancer-other Cancer Types,Pelvic Cancer

PROVIDER: 2465895 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

| 2463629 | ecrin-mdr-crc
2022-03-14 | GSE198266 | GEO
2010-08-03 | E-GEOD-12385 | biostudies-arrayexpress
2010-08-03 | GSE12385 | GEO
2022-04-28 | GSE201252 | GEO
2021-04-28 | GSE173429 | GEO
2010-08-03 | E-GEOD-12384 | biostudies-arrayexpress
2023-09-30 | GSE242357 | GEO
2023-09-30 | GSE242355 | GEO
2023-09-30 | GSE242354 | GEO